Articles tagged with Tuberculosis
Researchers have isolated monoclonal antibodies that effectively target and inhibit the growth of tuberculosis germs in laboratory mice. These biological antibiotics show promise as an alternative to traditional chemical antibiotics, offering a safer and more stable treatment option.
A new biomarker has been identified that can determine individual treatment duration for tuberculosis patients, reducing the need for prolonged therapy. The biomarker is based on an RNA signature from 22 genes and was developed using patient cohorts from Germany and Romania.
Research found fidaxomicin is more effective than existing TB medication at preventing growth of M. tuberculosis, including resistant strains. Fidaxomicin's in vitro activity was compared to rifampicin and showed promise as a potential new treatment for TB.
Researchers at the University of Sydney have developed a novel method to rapidly synthesize safe vaccines using protein-based immunization. The approach demonstrated strong immune response in mice against tuberculosis and has potential applications for respiratory diseases, including COVID-19.
Researchers propose a new TB drug targeting the FtsZ protein, inhibiting cell division and suppressing growth, with potential for long-term effectiveness. The compound has been identified through high-precision molecular simulations, offering a novel solution to the problem of drug resistance in TB.
Researchers developed a new imaging method to track antibiotic distribution in infected tissues, revealing that some antibiotics only partially penetrate infected cells. This discovery could lead to more targeted treatments and reduced risk of antibiotic resistance.
A new lung-on-chip model has provided insight into the body's response to early tuberculosis infection. The study revealed that alveolar epithelial cells play a crucial role in controlling bacterial growth by producing surfactant, which reduces surface tension and prevents uncontrolled bacterial growth.
Researchers at San Diego State University have uncovered a crucial clue to the mystery of TB's rapid resistance to antibiotics. They found that the pathogen uses an epigenetic domain to diversify and create multiple subpopulations with varying phenotypes, leading to drug resistance.
Research highlights the need for tuberculosis (TB) screening and ongoing clinical care for people on methotrexate living in areas with high TB prevalence. Methotrexate users taking corticosteroids or immunosuppressants are at increased risk of TB infection.
A study found that prenatal and early-life exposure to the Great Chinese Famine significantly increases the risk of pulmonary tuberculosis (PTB) in adulthood across two generations. Over 12,000 active PTB cases were attributed to famine exposure between 2005 and 2018 in Sichuan Province.
Researchers at MIT developed a machine-learning algorithm that can predict the effectiveness of drug compounds against tuberculosis and other diseases. The algorithm, which incorporates uncertainty values to account for data variability, identified promising compounds targeting a critical protein required by the bacteria.
A new TB vaccine developed by Dartmouth's Geisel School of Medicine has shown promising results in a Phase 2 trial, inducing immune responses against the disease. The vaccine was safe and well-tolerated, with minimal local reactions, and may prevent TB disease by inducing a favorable immune response.
Researchers at NTNU have filmed the process of tuberculosis infection in a cell, revealing how the bacterium evades the body's immune system. The study shows how TB bacteria hide inside macrophages and trigger an explosive immune response to spread further.
A new study from the Max Planck Institute of Geoanthropology has reconstructed a tuberculosis genome from the calcified lungs of a 17th-century bishop, supporting the idea that TB emerged within the last 6,000 years. The discovery sheds light on the origins of TB and challenges the prevailing assumption about its global distribution.
A new international study has shown that a newly developed treatment regimen for multidrug-resistant tuberculosis (MDR-TB) is highly effective, with an 85% success rate among patients with serious comorbidities. The regimens, bedaquiline and delamanid, offer a promising alternative to the historical standard of care, which has approxim...
A new vaccine candidate BCG::RD1 has shown highly protective effects against tuberculosis in older mice with type 2 diabetes. The vaccine acts on multiple immune cell subsets to mount a robust response against TB-causing bacteria.
The study found that implementing antiretroviral therapy (ART) for HIV and newer tuberculosis medications decreases the risk of death for adults with drug-resistant TB. Access to these life-saving medications varies widely globally.
A recent study published in Cell Reports Medicine found that the BCG vaccine is safe and does not increase the risk of COVID-19 symptoms. The research also suggests a cautiously positive picture, with lower numbers of sick people and extreme fatigue among vaccinated individuals during the pandemic.
Researchers at Johns Hopkins Medicine found that a next-generation cholesterol-lowering drug can lower blood cholesterol to safer levels faster when added to traditional therapies. The study showed significant reductions in LDL cholesterol during hospitalization and within a month following a heart attack, suggesting the drug is safe a...
Compounds tested for their potential as antibiotics have demonstrated promising activity against tuberculosis (TB), a deadly infectious disease caused by Mycobacterium tuberculosis. The study found that the compounds exploit well-known targets for drugs, including the bacterial enzyme DNA gyrase.
Researchers at Durham University have found a new toxin, called MenT, produced by the TB bacterium Mycobacterium tuberculosis. This toxin inhibits the use of amino acids needed for protein production, causing the bacteria to die. The discovery opens up new avenues for treating tuberculosis and other infections.
Scientists at Trinity College Dublin discovered a way to manipulate human immune responses to Mycobacterium tuberculosis, tipping the balance in favor of patients. The study used an epigenetic inhibitor to release pro-inflammatory signals that aid in clearing the infection, promoting future vaccine strategies.
A new technology dubbed MorphEUS enables rapid screening of drug candidates against Mycobcterium tuberculosis (M. tb), the bacterium that causes TB. It uses high throughput imaging and machine learning to uncover patterns in how antibacterials kill, improving the efficiency and effectiveness of treatment development.
A novel mouse model shows that contained and persistent yet non-pathogenic Mtb infection reduces tuberculosis disease burden after re-exposure. The study highlights the importance of innate immune responses in protecting against the disease.
A modelling study predicts that COVID-19 could lead to a significant increase in HIV, TB, and malaria deaths in low- and middle-income countries. The study suggests that prioritizing antiretroviral therapy, timely diagnosis and treatment of TB, and long-lasting insecticide-treated nets could mitigate the impact of the pandemic.
A preliminary study suggests that the Bacille Calmette-Guérin (BCG) vaccine, commonly administered to children in high-tuberculosis countries, may reduce mortality rates from COVID-19. The study found a correlation between higher BCG vaccination rates and lower peak mortality rates from COVID-19 in various countries.
UTEP research reveals a new target for tuberculosis drug development by investigating the mechanisms of Mtb pathogenesis and discovering that Nα-acetylation of EsxA drastically affects the course of infection. The study provides a beautiful story in the prestigious Journal of Biological Chemistry.
The global pandemic could significantly increase the global burden of tuberculosis due to disruptions to health services and delays in diagnosis and treatment. Researchers predict up to 110,000 additional TB deaths over five years, with 6,000 in China, 95,000 in India, and 13,000 in South Africa.
A study by universities of Bonn and Nijmegen found that BCG vaccination enhances immune response to multiple infections, including TB and Covid-19. The vaccine's effect is attributed to trained immunity, which allows innate immune cells to become more efficient independently of reinfection.
A recent study found that seven patient samples contained M. orygis, a subspecies not typically associated with human TB, indicating potential zoonotic transmission in India. The researchers suggest broadening the definition of zoonotic TB to include other MTBC subspecies capable of causing human disease.
A new study published in Annals of Internal Medicine finds that a 4-month rifampin regimen is cheaper and more effective than a 9-month course of isoniazid for treating latent tuberculosis. The treatment has the potential to change the way latent tuberculosis is treated, with significant cost savings for healthcare systems.
The tuberculosis pathogen Mycobacterium tuberculosis can survive for a longer period of time when combined with other bacteria in the air. This is because larger aerosol particles from mycobacterial clusters are produced together with components of dead cells, making them more viable in the air.
A new ancestral lineage of tuberculosis has been found in East Africa, with genome analyses suggesting a unique origin. The discovery reinforces the hypothesis of an East African origin for the disease and provides insights into its evolution.
Scientists at Trinity College Dublin have discovered that the iron chelator DFX supports lung immunity against tuberculosis by driving the activation of glycolysis, a key metabolic pathway. This process helps immune cells make energy to fight infection and improves macrophages' ability to address TB infection.
A five-year study has identified the mechanism behind the BCG vaccine's unexpected protection against diseases other than TB in newborns. The researchers found that BCG triggers a rapid increase in neutrophils, white blood cells that fight invading pathogens.
A new study confirms that ethambutol, a key TB drug, targets specific proteins in the bacteria. Researchers used cryogenic electron microscopy and x-ray imaging to show how the drug binds to and inactivates these proteins, producing crucial components of the TB cell wall.
Researchers discovered a novel mechanism for Mycobacterium tuberculosis to import vitamin B12, a crucial nutrient for the pathogen's growth. The Rv1819c protein was found to be capable of importing B12 and transporting other molecules, making it an attractive target for developing anti-TB drugs.
A study found that UK healthcare policies restricting access for non-UK born patients may lead to delays in TB diagnosis and treatment. The median time to treatment increased by 20 days after the policy was introduced.
Researchers identified a protein responsible for transporting iron into bacteria that causes tuberculosis. Inhibiting this transport process could lead to new drug targets and novel treatments.
Scientists discovered a novel transport protein in TB bacteria that imports vitamin B12 and bleomycin with a large water-filled cavity. This non-selective transporter may be common in bacteria and human cells, offering new insights into tuberculosis physiology and potential treatment strategies.
Researchers at SLAC National Accelerator Laboratory have discovered a giant cavity in a protein that transports a wide range of molecules, including vitamin B12 and antibiotics, into the bacterial cell. The discovery could lead to new ways to treat tuberculosis, but further studies are needed to understand the protein's capabilities.
A study by Singapore researchers found that underweight diabetics have an eight-fold increase in risk of contracting active TB compared to obese individuals. The study highlights the importance of early diagnosis and targeted screening for this vulnerable population.
Researchers found that a key TB antibiotic can't irreversibly inhibit an enzyme, instead allowing it to function again through hydrolysis. This discovery could lead to the development of improved versions of the drug and new treatments for antibiotic-resistant bacteria.
Researchers discovered a protein called gamma subunit that controls fatty acid synthase function in mycobacteria, allowing for the inhibition of pathogen proliferation without affecting human cells. This breakthrough could lead to new therapeutic approaches against tuberculosis and provide insights into cancer treatment.
Researchers at the University of Texas at Dallas identified a molecule that induces coughing in tuberculosis patients, providing a potential target for treatment and prevention. The discovery could help reduce the spread of TB, which kills over 1.3 million people worldwide annually.
Tuberculosis bacteria produce a molecule called sulfolipid-1 (SL-1) that triggers coughing in infected animals and human cells, facilitating the spread of disease. The findings could lead to new treatments to prevent tuberculosis transmission.
A family of porin-like proteins helps M. tuberculosis acquire essential nutrients while evading antibiotics and immune attacks. Researchers discovered the unique role of PE/PPE proteins in ferrying vital nutrients across the cell's waxy wall.
Research led by Andries Steyn found that Mtb bacteria induce increased hydrogen sulfide production in human macrophages, increasing pathogenesis and virulence. The study suggests that targeting hydrogen sulfide production may be useful for managing tuberculosis and other microbial infections.
Researchers developed a noninvasive imaging technique to monitor rifampin levels in TB patients. The dynamic 11C-rifampin PET/CT tool successfully tracked the movement of the tagged drug into lesions and cavities, revealing low penetration rates that can change over time.
Researchers at the University of Southampton have identified a potential link between new cancer treatments and tuberculosis. The study found that immune checkpoint inhibitors can lead to an excessive immune response, increasing the growth of bacteria that cause TB disease.
Recent advances in TB diagnostics, treatments and prevention offer hope for reducing and ultimately eliminating the burden of tuberculosis. The National Institute of Allergy and Infectious Diseases has made significant progress in improving TB diagnostics, therapeutic regimens and prevention approaches.
The ERA4TB project aims to develop comprehensive treatments against tuberculosis by adopting a parallel development pathway that allows for simultaneous research of multiple potentially effective molecules. This approach will significantly reduce the time taken developing new combined treatments needed to eradicate TB.
A new study maps TB immune responses in diverse models including genetically diverse mice and blood samples from adolescents with TB. The study reveals similarities and differences between human, mouse, and macaque responses, providing valuable insights for developing effective therapies.
Commonly used TB vaccines differ significantly in live bacteria content and cytokine responses, sparking concerns about their equivalence. The study highlights the need for a large-scale clinical trial to standardize BCG vaccine formulations.
Researchers discovered that a 'frameshift mutation' in TB bacteria's RpoB gene makes them resistant to rifampicin. The mutation suppresses the effect of the frameshift, allowing the bacteria to survive and thrive.
A blood test using eight gene signatures can predict the onset of tuberculosis three to six months before symptoms appear. This finding could help target antibiotics and save lives, particularly by identifying individuals at risk of developing TB disease after being infected with the bacteria.
Researchers at the University of Dundee are working on a new effort to tackle tuberculosis, identifying new treatment options for the disease. With a $3 million grant from the Bill & Melinda Gates Foundation, they aim to improve drug discovery and develop new candidate drugs to treat TB.
Researchers found that intravenous BCG vaccination significantly increased protection against TB in rhesus macaques. The study showed that IV BCG elicited strong, sustained T cell responses in the lungs, leading to a high degree of protection against infection and disease.
A new study found that delivering the TB vaccine intravenously dramatically improves its potency, offering nearly full protection against TB in monkeys. The vaccine was highly effective when administered via injection into a vein, reducing bacterial burden by 100,000-fold and inflammation in lungs to near zero.
A compound in green tea has been shown to inhibit the growth of tuberculosis-causing bacteria by disrupting energy production. The discovery could lead to the development of new drugs to combat multi-drug resistant TB.